Search Results

You are looking at 1 - 10 of 241 items for :

  • "Hodgkin lymphoma" x
Clear All
Full access

Leona Holmberg and David G. Maloney

Treatment for Hodgkin lymphoma (HL) has improved so that most patients, even those with high-risk disease, are now cured with primary therapy. 1 , 2 However, for patients with primary refractory disease, or those experiencing relapse after

Full access

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Nadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Christina Tsien, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns and Hema Sundar

Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Most patients are diagnosed between 15 and 30 years of age, followed by another peak in adults aged 55 years or older. In 2015, an estimated 9,050 people will

Full access

Leo I. Gordon

“There are a number of salvage chemotherapy regimens in relapsed or refractory [R/R] Hodgkin lymphoma [HL],” revealed Leo I. Gordon, MD, Abby and John Friend Professor of Cancer Research and Professor of Medicine, Division of Hematology

Full access

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Lawrence Weiss, Jane N. Winter and Joachim Yahalom

NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A

Full access

Shira Dinner and Ranjana Advani

Discuss novel agents that target the rare malignant Reed-Sternberg (HRS) cell surface, a unique pathophysiologic feature of HL Classical Hodgkin lymphoma (HL) is one of the most curable cancers. Patients whose disease relapses and fails to respond to

Full access

Joachim Yahalom

. Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? J Natl Cancer Inst 2005 ; 97 : 1394 – 1395 . 5. Canellos GP . Chemotherapy alone for early Hodgkin's lymphoma: an emerging option . J Clin Oncol 2005 ; 23 : 4574 – 4576

Full access

Ranjana Advani, Weiyun Z. Ai and Sandra J. Horning

. 19. Johnson P Hoskin P Horwich A . Stanford V (SV) regimen versus ABVD for the treatment of advanced Hodgkin lymphoma (HL): results of a UK NCRI/LTO randomised phase II trial [abstract] . Blood 2004 ; 104 Abstract 311 . 20. Gobbi

Full access

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, William G. Wierda, Joachim Yahalom and Nadeem Zafar

NCCN Clinical Practice Guidelines in Oncology for Non-Hodgkin's Lymphomas NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform

Full access

Debra L. Friedman and Louis S. Constine

. J Clin Oncol 2000 ; 18 : 2435 – 2443 . 5. Hill DA Gilbert E Dores GM . Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors . Blood 2005 ; 106 : 3358 – 3365 . 6. Swerdlow AJ

Full access

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Robert Chen, Bouthaina Dabaja, Robert Dean, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Kami Maddocks, David G. Maloney, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Rachel Rabinovitch, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns and Ndiya Ogba

Hodgkin Lymphoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Hodgkin Lymphoma NCCN Guidelines Insights : Hodgkin Lymphoma, Version 1.2018 Version 1.2018 © National Comprehensive Cancer